LaVoieHealthScience Client Spotlight Following is a Q&A with Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics (NASDAQ: OTLK), a late-stage clinical biotech company focused on developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg to treat wet age-related macular degeneration (wet AMD) and other retinal diseases. By way of background for our readers, age-related macular […]